Skip to content

Advertisement

Open Access

Corynebacterium glutamicum as platform for the production of hydroxybenzoic acids

Microbial Cell Factories201817:70

https://doi.org/10.1186/s12934-018-0923-x

Received: 1 March 2018

Accepted: 5 May 2018

Published: 12 May 2018

Abstract

Background

Hydroxybenzoic acids are industrially relevant aromatic compounds, which also play key roles in the microbial carbon metabolism, e.g., as precursors for the synthesis of cofactors or metal-chelating molecules. Due to its pronounced resistance to aromatics Corynebacterium glutamicum represents an interesting platform for production of these compounds. Unfortunately, a complex catabolic network for aromatic molecules prevents application of C. glutamicum for microbial production of aromatic compounds other than aromatic amino acids, which cannot be metabolized by this microorganism.

Results

We completed the construction of the platform strain C. glutamicum DelAro5, in which the deletion of altogether 27 genes in five gene clusters abolished most of the peripheral and central catabolic pathways for aromatic compounds known in this microorganism. The obtained strain was subsequently applied for the production of 2-hydroxybenzoate (salicylate), 3-hydroxybenzoate, 4-hydroxybenzoate and protocatechuate, which all derive from intermediates of the aromatic amino acid-forming shikimate pathway. For an optimal connection of the designed hydroxybenzoate production pathways to the host metabolism, C. glutamicum was additionally engineered towards increased supply of the shikimate pathway substrates erythrose-4-phosphate and phosphoenolpyruvate by manipulation of the glucose transport and key enzymatic activities of the central carbon metabolism. With an optimized genetic background the constructed strains produced 0.01 g/L (0.07 mM) 2-hydroxybenzoate, 0.3 g/L (2.2 mM) 3-hydroxybenzoate, 2.0 g/L (13.0 mM) protocatechuate and 3.3 g/L (23.9 mM) 4-hydroxybenzoate in shaking flasks.

Conclusion

By abolishing its natural catabolic network for aromatic compounds, C. glutamicum was turned into a versatile microbial platform for aromatics production, which could be exemplarily demonstrated by rapidly engineering this platform organism towards producing four biotechnologically interesting hydroxybenzoates. Production of these compounds was optimized following different metabolic engineering strategies leading to increased precursor availability. The constructed C. glutamicum strains are promising hosts for the production of hydroxybenzoates and other aromatic compounds at larger scales.

Keywords

Hydroxybenzoic acids Corynebacterium glutamicum Shikimate pathwayMetabolic engineeringProtocatechuate4-hydroxybenzoate

Background

Aromatic compounds represent a major class of industrially relevant hydrocarbons, which are for the most part derived from the benzene-, toluene-, ethylbenzene- and xylene- (BTEX) fraction of petroleum [1]. Oxidation of these compounds leads to hydroxybenzoic acids, which serve as building blocks for the production of plastics and fibers, cosmetics, pharmaceuticals, as well as food and feed supplements [2]. However, growing environmental concerns are the main driving force towards establishing sustainable production processes from renewable carbon sources [3]. In this context, microorganisms are recognized as valuable alternative sources for such products as they naturally synthesize a broad range of different aromatic compounds.

The shikimate pathway is primarily responsible for the synthesis of the three aromatic amino acids l-phenylalanine, l-tyrosine and l-tryptophan [4], but intermediates of this pathway are also required for the synthesis of vitamins (e.g., ubiquinone or folate), siderophores or secondary metabolites (e.g., antibiotics) [59]. In this context, many shikimate pathway intermediates are first converted to hydroxybenzoates, which then serve as precursor molecules for synthesis of the above-mentioned functional molecules.

Several enzymes catalyzing the initial hydroxybenzoate-forming steps were studied detail, which allows application of these enzymes for the microbial production of various hydroxybenzoates. For the most part, engineering efforts focused on using Escherichia coli and Saccharomyces cerevisiae as production hosts [10]. The obtained strains were able to produce a broad range of mono- or dihydroxylated benzoic acids, but also phenols (e.g., catechol) or benzaldehydes (e.g., vanillin) became accessible [11, 12]. In other studies, aromatic compounds did not represent the final products but served as precursors for the production of dicarboxylic acids such as cis,cis-muconic acid and adipic acid with engineered microorganisms [13].

The Gram-positive prokaryote Corynebacterium glutamicum has a long standing history in the industrial production of amino acids [14, 15]. In particular l-glutamate and l-lysine are produced at a million ton-scale with this bacterium, but engineered strains for the production of other proteinogenic amino acids are also available [16, 17]. In the course of optimizing aromatic amino acid production in C. glutamicum, individual reactions of the shikimate pathway as well as the regulation of this pathway were studied in detail [18]. More recently, C. glutamicum was also engineered towards producing shikimate pathway intermediates (e.g., shikimate) and aromatic compounds derived thereof (e.g., p-aminobenzoate) [19, 20]. Before that, there was less effort to engineer C. glutamicum towards synthesis of such compounds, which can be attributed to the complex network of catabolic pathways for aromatics present in this soil bacterium [21]. C. glutamicum is not only capable of degrading aromatic compounds for detoxification purposes, but can also utilize many aromatic compounds such as p-coumaric acid, vanillate, p-cresol, 3-hydroxybenzoate, 4-hydroxybenzoate and protocatechuate as sole carbon and energy source [2225]. As C. glutamicum was found to have a pronounced resistance to this class of compounds [26], it is reasonable to use C. glutamicum as production host. However, any attempt to produce aromatic compounds would require elimination of the catabolic pathways competing for the desired products. In a previous study, we constructed the platform strain C. glutamicum DelAro4 for the production of plant polyphenols [27]. Key to success was elimination of a catabolic pathway for phenylpropanoids such as cinnamic acid, p-coumaric acid and caffeic acid, which represent important precursor molecules for plant polyphenols.

In this study, we abolished additional catabolic pathways in C. glutamicum DelAro4 and constructed a platform strain, which was subsequently engineered towards producing 2-hydroxybenzoate (2-HB, salicylate), 3-hydroxybenzoate (3-HB), 4-hydroxybenzoate (4-HB) and 3,4-dihydroxybenzoate (protocatechuate, PC). Furthermore, we followed different engineering strategies to ensure increased availability of relevant endogenous precursor molecules for improving overall product synthesis with this organism.

Methods

Bacterial strains, plasmids, media and growth conditions

All bacterial strains and plasmids used in this study and their relevant characteristics are listed in Table 1. C. glutamicum was routinely cultivated aerobically at 30 °C in brain heart infusion (BHI) medium (Difco Laboratories, Detroit, USA) or defined CGXII medium with 4% glucose as sole carbon and energy source [28]. E. coli DH5α used for plasmid constructions was cultivated in LB medium [29] at 37 °C. Where appropriate, kanamycin (50 µg/mL for E. coli or 25 µg/mL for C. glutamicum) or spectinomycin (100 µg/mL for E. coli and C. glutamicum) was added to the medium. Bacterial growth was followed by measuring the optical density at 600 nm (OD600). C. glutamicum was grown for 6 - 8 h in test tubes with 5 mL BHI medium on a rotary shaker at 170 rpm (first preculture) and was subsequently inoculated into 50 mL defined CGXII medium with 4% glucose in 500 mL baffled Erlenmeyer flasks (second preculture). The cell suspensions were cultivated overnight on a rotary shaker at 130 rpm. The main culture was inoculated to an OD600 of 5.0 in defined CGXII medium with 4% (222 mM) glucose. Heterologous gene expression was induced 1 h after inoculation using the indicated amount of IPTG.
Table 1

Strains and plasmids used in this study

Strain or plasmid

Relevant characteristics

Source or reference

E. coli strains

 DH5α

F– Φ80lacZΔM15 Δ(lacZYA-argF)U169 recA1 endA1 hsdR17 (rK–, mK +) phoA supE44 λ– thi-1 gyrA96 relA1

Invitrogen (Karlsruhe, Germany)

C. glutamicum strains

 MB001(DE3)

prophage-free derivate of ATCC 13032 with chromosomal expression of T7 RNA polymerase gene under control of PlacUV5 (IPTG-inducible)

[65]

 DelAro4

MB001(DE3) derivative with in-frame deletions of cg0344-cg0347, cg2625-cg2640, cg1226 and cg0502

[27]

 DelAro5

DelAro4 derivative with in-frame deletion of cg3349-cg3354

This study

 DelAro5 C7

DelAro5 derivative with an exchange of the native promoter of the citrate synthase gene gltA by the dapA promoter variant C7

This study

 DelAro5 PO6-iolT1

DelAro5 derivative with two point mutations in the promoter of the inositol transporter gene iolT1, abolishes repression of iolT1 by IolR

This study

 DelAro5 C7 PO6-iolT1

DelAro5 derivative with combined modifications of DelAro5 C7 and DelAro5 PO6-iolT1

This study

Plasmids

 pMKEx2

kanr; E. coli-C. glutamicum shuttle vector (lacI, PT7, lacO1, pHM1519 ori Cg ; pACYC177 ori Ec )

[65]

 pMKEx2_aroF*_qsuB

pMKEx2 derivate for expression of genes coding for AroF* from E. coli (codon-optimized gene) and for QsuB of C. glutamicum (native gene)

This study

 pMKEx2_aroF*_irp9

pMKEx2 derivate for expression of genes coding for AroF* from E. coli (codon-optimized) and for Irp9 from Yersinia enterocolitica (codon-optimized)

This study

 pMKEx2_aroF*_hyg5

pMKEx2 derivate for expression of genes coding for AroF* from E. coli (codon-optimized) and for Hyg5 from Streptomyces hygroscopicus (codon-optimized)

This study

 pMKEx2_aroF*_ubiC

pMKEx2 derivate for expression of genes coding for AroF* (codon-optimized) and for UbiC (native gene) from E. coli

This study

 pMKEx2_aroH_ubiC

pMKEx2 derivate for expression of genes coding for AroH (native gene) and for UbiC (native gene) from E. coli

This study

 pEKEx3

specr; E. coli-C. glutamicum shuttle vector (lacI, P tac , lacO1, pBL1ori Cg ; pUCori Ec )

[66]

 pEKEx3_tkt

pEKEx3 derivate for overexpression of the transketolase gene tkt of C. glutamicum (the TTG start codon of tkt was replaced for ATG)

This study

 pK19mobsacB

kan r ; vector for allelic exchange in C. glutamicum (pK18 oriV Ec sacB lacZα)

[33]

 pK19mobsacB_cg3349-54-updown

pK19mobsacB derivate for the in-frame deletion of cg3349-54

This study

 pK19mobsacB_PO6-iolT1

pK19mobsacB derivate for introducing the mutagenized operator sequence into the iolT1 promoter region

[48]

 pK19mobsacB_ΔP gltA :P dapA -C7

pK19mobsacB derivate for exchanging the native gltA promoter for the dapA promoter variant C7

[50]

kanr kanamycin resistance, specr spectinomycin resistance

Construction of plasmids and strains

Standard protocols of molecular cloning, such as PCR, DNA restriction, and ligation [30] were carried out for recombinant DNA work. Techniques specific for C. glutamicum, e.g., electroporation for transformation of strains, were performed as described previously [31]. All enzymes were obtained from ThermoScientific (Schwerte, Germany). Codon-optimized synthetic genes for C. glutamicum ATCC 13032 were obtained from LifeTechnologies (Darmstadt, Germany). Genes were amplified by PCR using primers containing unique restriction sites (Table 2). PCR products were then used for cloning of genes into plasmid vectors using the introduced restrictions site. For the assembly of multiple genes and for elimination of undesired internal restriction sites Electra Cloning was used [32]. This cloning strategy is based on the class IIS restriction enzyme SapI, generating 5′-overhangs, which can be freely designed. In-frame gene deletions and nucleotide substitutions in the genome of C. glutamicum were performed using the pK19mobsacB system [33] by a two-step homologous recombination method described previously [34]. All constructed plasmids were finally verified by DNA sequencing at Eurofins Genomics (Ebersberg, Germany).
Table 2

Oligonucleotides used in this study

Oligonucleotide

Sequence (5′–3′)

Restriction site

del_cg3349-54-up-s

ACCAAGCTTCATTTTCTAGTTGAGATTCATTATCATAACGCTTGACAGTACAACTATGTC

HindIII

del_cg3349-54-up-as

GCTTCCGGGGTGAATGACGGAGCCGCTGCGGAGGTTCCAGAGCCACCGCGCTG

del_cg3349-54-down-s

CGCAGCGGCTCCGTCATTCACCCCGGAAGCTGGCGCTACGCCCTCCTCGAAC

del_cg3349-54-down-as

ACCTCTAGATTTCTGTCTTGAGGGTTCGTGGGGGCTG

XbaI

check-cg3349-54-s

AAAGGCTCCATGAATTCCTCACGGAGGATCTC

check-cg3349-54-as

ACATCACAAGTAGAAACCCGCATTTTCTGTAGTTTTTAC

(A)-aroF*-s

TTCGCTCTTCAAAGCTGCTTAAGGAGGCTATCTATGACCGATGAACAGGTGCTGATGACCCCAG

SapI

(A)-aroF*-as

TACGCTCTTCTGATTTATGCCACGCGTGCGGTCAGCTG

SapI

(A)-aroH-s

TTCGCTCTTCAAAGTATACCATGGTAAGGAGGTTCAGCATGAACAGAACTGACGAACTCCGTACTGCGCGTATTG

SapI

(A)-aroH-as

TACGCTCTTCTGATTTAGAAGCGGGTATCTACCGCAGAGGCGAGTTTTTC

SapI

(B)-qsuB-s

TTCGCTCTTCAATCTCTATCAAGGAGGATCGGCATGCGTACATCCATTGCCACTGTTTGTTTGTC

SapI

(B)-qsuB-as

TACGCTCTTCTTCGTTAGTTTGGGATTCCCCGCTCGAGGTC

SapI

(B)-irp9-s

TTCGCTCTTCAATCTCTATCAAGGAGGATCGGCATGAAGATCTCCGAGTTCCTCCACCTGGCAC

SapI

(B)-irp9-as

TACGCTCTTCTTCGTTACACCATCAGGTATGGTGCAATGGAGGCCAGCTTTTCGCGAGTTTCG

SapI

(B)-hyg5-s

TTCGCTCTTCAATCTCTATCAAGGAGGATCGGCATGAACCCATCCTCCTTGGTGCTGAAC

SapI

(B)-hyg5-as

TACGCTCTTCTTCGTTACATGACCACGCCTTCGATTTCCACGAG

SapI

(B)-ubiC-s

TTCGCTCTTCAATCTCTATCAAGGAGGATCGGCATGTCACACCCCGCGTTAACGCAACTG

SapI

(B)-ubiC-as

TACGCTCTTCTTCGTTAGTACAACGGTGACGCCGGTAAAAACAGTTCTGTTAG

SapI

tkt’-s

CATGGATCCAAGGAGGTTCAGCATGACCACCTTGACGCTGTCACCTGAACTTCAG

BamHI

tkt’-as

AGAGCTCTTCAGCCCATAGCGTGCTCACGGATACCGAAGTG

SapI

‘tkt-s

TTTGCTCTTCTGGCTCCATCCTCAACGGCATTTCCCTCC

SapI

‘tkt-as

TCTGAATTCTTAACCGTTAATGGAGTCCTTGGCCGCTGCCAC

EcoRI

pMKEx2_own-s

CCCTCAAGACCCGTTTAGAGGC

pMKEx2_own-as

TTAATACGACTCACTATAGGGGAATTGTGAGC

pEKEx3-s

GCAAATATTCTGAAATGAGCTGTTGACAATTAATCATC

pEKEx3-as

CGTTCTGATTTAATCTGTATCAGGCTGAAAATCTTCTC

Restriction sites are underlined; SapI cuts outside of its recognition site, the obtained 5′-overhangs after SapI cleavage used for Electra Cloning are shown in bold. In case of native tkt two separate PCR fragments were assembled using Electra Cloning to eliminate an internal SapI restriction site

LC–MS analysis for quantification of hydroxybenzoates

Hydroxybenzoates 2-HB, 3-HB, 4-HB and PC were quantified in the culture supernatant by LC–MS (Additional file 1: Figures S3–S7) using an Agilent ultra-high-performance LC 1290 Infinity System coupled to a 6130 Quadrupole LC–MS System (Waldbronn, Germany). LC separation was carried out using a Kinetex 1.7u C18 100 Å pore size column (50 mm by 2.1 mm (internal diameter)) (Phenomenex, Torrance, CA, USA) at 50 °C. For elution, 0.1% acetic acid (solvent A) and acetonitrile supplemented with 0.1% acetic acid (solvent B) were applied as the mobile phases at a flow rate of 0.3 mL/min. A gradient was used, where the amount of solvent B was increased stepwise: minute 0–6: 5–30%, minute 6–7: 30–50%, minute 7–8: 50–100% and minute 8–8.5: 100–5%. The mass spectrometer was operated in the negative electrospray ionization (ESI) mode, and data acquisition was performed in selected-ion-monitoring (SIM) mode. Authentic metabolite standards were purchased from Sigma-Aldrich (Schnelldorf, Germany) or from Alfa Aesar (Karlsruhe, Germany). Area values for [M−H] mass signals were linear up to metabolite concentrations of at least 250 mg/L. Benzoic acid (final concentration 100 mg/L) was used as internal standard. Calibration curves were calculated based on analyte/internal standard ratios for the obtained area values.

Results

Pathway design for hydroxybenzoate production

All four desired hydroxybenzoates, PC, 2-HB, 3-HB, and 4-HB can be synthesized from two different intermediates of the shikimate pathway (Fig. 1). PC can be derived from 3-dehydroshikimate by an enzyme-catalyzed dehydration directly yielding this dihydroxybenzoate. C. glutamicum possesses the 3-dehydroshikimate dehydratase QsuB (Uniprot entry Q8NT86) normally involved in the pathway for quinate and shikimate degradation, which is known to catalyze this irreversible reaction [35]. The three monohydroxylated benzoates 2-, 3- and 4-HB can be produced from the shikimate pathway intermediate chorismate, but for their synthesis no endogenous enzymes can be recruited (Fig. 1). A detailed analysis of chorismate-converting enzymes identified the bifunctional isochorismate synthase/isochorismate pyruvate lyase (salicylate synthase) Irp9 (Uniprot entry Q9X9I8) in Yersinia enterocolitica, which first isomerizes chorismate to isochorismate and subsequently eliminates pyruvate yielding 2-HB [36] (Fig. 1). In Streptomyces hygroscopicus the chorismatase (3-hydroxybenzoate synthase) Hyg5 (Uniprot entry O30478) is known to catalyze hydrolysis and concomitant dehydration of the same compound ultimately leading to 3-HB [37]. Finally, 4-HB can be synthesized from chorismate by directly eliminating pyruvate through the enzymatic activity of a chorismate pyruvate lyase (4-hydroxybenzoate synthase) such as UbiC (Uniprot entry P26602), which is involved in ubiquinone biosynthesis in E. coli [38].
Figure 1
Fig. 1

Schematic representation of the shikimate pathway in C. glutamicum and additionally introduced enzymatic steps for hydroxybenzoate production. AroF*, AroH: 3-deoxy-d-arabinoheptulosonate-7-phosphate synthase, DAHP: 3-deoxy-d-arabinoheptulosonate-7-phosphate, Hyg5: chorismatase (3-hydroxybenzoate synthase), EPSP: 5-enolpyruvyl-shikimate-3-phosphate, Irp9: isochorismate synthase/isochorismate pyruvate lyase (salicylate synthase), PEP: phosphoenolpyruvate, QsuB: 3-dehydroshikimate dehydratase, UbiC: chorismate pyruvate lyase (4-hydroxybenzoate synthase). Irp9, Hyg5 and UbiC lead to the formation of pyruvate as a second product, which is not depicted

An updated C. glutamicum strain for the production of aromatic compounds

In a preceding study, we observed that activity of the phenylpropanoid degradation pathway (Phd-pathway), a catabolic pathway for phenylpropanoids in C. glutamicum, nearly completely abolished production of phenylpropanoid-derived plant polyphenols with this organism [27]. The Phd-pathway ultimately yields different (hydroxy-) benzoic acids, which can be further metabolized by C. glutamicum employing the β-ketoadipate pathway. Based on this observation, altogether 21 genes involved in catabolism of aromatic compounds were deleted in the genome of C. glutamicum MB001(DE3), a prophage-free derivative of C. glutamicum ATCC 13032, including phdBCDE (cg0344-47), qsuB (cg0502), pobA (cg1226) and pcaFDOpcaCBGH–cg2633–catCBAbenABCD (cg2625-40) (Fig. 2). This strain termed C. glutamicum DelAro4 was successfully applied for plant polyphenol synthesis and represents a suitable starting point for the microbial production of hydroxybenzoic acids as it is unable to degrade 4-HB and PC. However, C. glutamicum DelAro4 should still be able to metabolize 3-HB by the gentisate pathway, which finally leads to fumarate and pyruvate [39]. The enzymes of the gentisate pathway are encoded by genes of the nagIKLnagRnagTgenH gene cluster (cg3349-54). In order to prevent any product degradation during the targeted 3-HB production the whole gene cluster was deleted in C. glutamicum DelAro4 yielding C. glutamicum DelAro5 (Fig. 2 and Additional file 1: Figure S1). In a cultivation experiment using defined CGXII medium supplemented with 2.8 g/L (20 mM) 3-HB as sole carbon and energy source the reference strain C. glutamicum MB001(DE3) reached a final OD600 of 10.2 after 24 h (initial OD600 was 0.5) and a maximal growth rate of 0.19 h−1 (Additional file 1: Figure S2). In the supernatant of C. glutamicum MB001(DE3) no 3-HB could be detected at the end of the cultivation. In contrast, C. glutamicum DelAro5 did not show any growth on 3-HB (Additional file 1: Figure S2) and no decrease of 3-HB concentration in the culture medium could be observed (data not shown).
Figure 2
Fig. 2

Deleted gene clusters and thus abolished catabolic pathways for aromatic compounds in C. glutamicum DelAro5. During the construction of C. glutamicum DelAro5 altogether 27 genes involved in the catabolic network for aromatic compounds and organized in the five clusters were deleted. Among these, genes coding for enzymes involved in the degradation of the depicted hydroxybenzoates are shown in the same color (orange: β-ketoadipate pathway, green: gentisate pathway). No catabolic pathway for 2-hydroxybenzoate is present in C. glutamicum. Genes shown in gray code for enzymes involved in catabolic pathways for phenylpropanoids, shikimate, catechol and benzoate

It has not been tested whether C. glutamicum is capable of metabolizing 2-HB. However, cultivation of the reference strain C. glutamicum MB001(DE3) in defined CGXII medium supplemented with 2.8 g/L (20 mM) 2-HB showed that C. glutamicum is unable to grow with this hydroxybenzoate as sole carbon and energy source. In the culture supernatant obtained after 24 h of cultivation no decrease of the initial concentration of 2-HB could be observed (data not shown).

Hydroxybenzoate production in C. glutamicum DelAro5

Establishing hydroxybenzoate production in C. glutamicum via the designed pathways required an increased supply of shikimate pathway intermediates by increasing the flux into the shikimate pathway. In C. glutamicum, the carbon flux into the shikimate pathway is controlled by allosteric product inhibition of two 3-deoxy-d-arabinoheptulosonate-7-phosphate (DAHP) synthase isoenzymes, which catalyze the initial committed step in this pathway [40]. In order to allow for an increased flux in the pathway the DAHP synthases AroH or AroF from E. coli were evaluated for an application during heterologous hydroxybenzoic acid production with C. glutamicum (Fig. 1). AroH (Uniprot entry P00887) is only feedback-inhibited by l-tryptophan, but not by the two other aromatic amino acids [41]. In C. glutamicum, expression of genes coding for enzymes of the l-tryptophan biosynthetic pathway is repressed by the regulator LtbR when sufficient l-tryptophan is available [42]. Therefore, it was expected that an increased flux into the shikimate pathway does not lead to a significant overproduction of l-tryptophan, which in turn would also inhibit AroH activity. The l-tyrosine-sensitive DAHP synthase AroF (Uniprot entry P00888) from E. coli represented a suitable alternative since it could be shown that a truncated version of this enzyme lacking the 11 N-terminal amino acids (designated AroF*) is no longer feedback-regulated by l-tyrosine [43]. For production of different hydroxybenzoates in C. glutamicum either aroH or aroF* was expressed in combination with a second gene coding for an enzyme capable of converting shikimate pathway intermediates to the desired hydroxybenzoate.

Genes coding for the above-mentioned (heterologous) enzymes QsuB (3-dehydroshikimate dehydratase), Irp9 (salicylate synthase), Hyg5 (3-hydroxybenzoate synthase) and UbiC (4-hydroxybenzoate synthase) were chosen for expression in C. glutamicum. In case of aroF*, irp9 and hyg5 codon-optimized genes were used. It could be already shown that heterologous expression of the E. coli genes aroH and ubiC yielded functional enzymes in C. glutamicum [27, 44]. Thus, both genes were picked for establishing hydroxybenzoate production in C. glutamicum. For plasmid constructions, aroH or aroF* were cloned in combination with qsuB, irp9, hyg5 or ubiC as synthetic bicistronic operons into the plasmid pMKEx2 enabling IPTG-inducible expression using the strong T7 promoter. Strength of (heterologous) gene expression was optimized for each of the constructed strains separately. The best-performing combinations of heterologous genes and inducer concentration eventually leading to the highest hydroxybenzoate titers in C. glutamicum DelAro5 are listed in Table 3.
Table 3

Genes and induction conditions leading to the highest obtained hydroxybenzoate product titers in C. glutamicum DelAro5

Product

DAHP synthase

Codon-optimization

Hydroxybenzoate-forming enzyme

Codon-optimization

IPTG concentration (µM)

Product titer (g/L)

protocatechuate

aroF*

Yes

qsuB

Noa

20

1.47

2-hydroxybenzoate

aroF*

Yes

irp9

Yes

20

0.01

3-hydroxybenzoate

aroF*

Yes

hyg5

Yes

40

0.26

4-hydroxybenzoate

aroH

No

ubiC

No

1000

2.32

aEndogenous gene (cg0502)

Under optimized conditions, expression of irp9 in combination with aroF* enabled accumulation of 10 mg/L (0.07 mM) 2-HB in the culture supernatant of C. glutamicum DelAro5 pMKEx2_aroF*_irp9 during shaking flask cultivations. In the same strain harboring pMKEx2_aroF*_hyg5 instead, 0.26 g/L (1.9 mM) 3-HB was produced, whereas heterologous gene expression from the plasmid pMKEx2_aroF*_qsuB allowed for a maximal product titer of 1.5 g/L (9.7 mM) PC under the same cultivation conditions. In case of 4-HB, a higher product titer was achieved when, instead of the codon-optimized aroF* gene, the native gene aroH was expressed in combination with ubiC. In the corresponding strain C. glutamicum DelAro5 pMKEx2_aroH_ubiC full induction with 1 mM IPTG allowed for the highest obtained product titer of 2.3 g/L (16.7 mM) 4-HB.

Engineering of the host towards increased supply of shikimate pathway precursors

In case of all four hydroxybenzoates, expression of two (heterologous) genes was sufficient for enabling product formation with the platform strain C. glutamicum DelAro5. For PC and 4-HB, g/L-scale product titers could be determined. With the aim to further increase overall product formation, additional engineering of the host metabolism was pursuit to provide increased levels of erythrose-4-phosphate (E4P) and phosphoenolpyruvate (PEP) for the already deregulated initial step of the shikimate pathway. To this end, we tested different strategies for manipulating substrate transport capabilities and key enzymatic activities of the central carbon metabolism, which allow for an increased carbon flux into the shikimate pathway.

In C. glutamicum, glucose is taken up by the glucose-dependent phosphotransferase system consuming PEP as phosphate donor [45]. This means that for each glucose molecule taken up and converted to glucose-6-phosphate, one molecule of PEP is simultaneously converted to pyruvate. It was found that the myo-inositol/proton symporter IolT1 in C. glutamicum is capable of importing glucose by a phosphotransferase-independent transport mechanism [46] (Fig. 3). Expression of the corresponding iolT1 gene is known to be repressed by the regulator IolR in absence of myo-inositol [47]. Recently, IolR-derepression of iolT1 was realized in C. glutamicum by targeted mutagenesis of the IolR-operator sequence (designated O6) in the iolT1-promoter region [48]. This genetic modification abolished IolR-binding, allowed constitutive expression of iolT1 in absence of myo-inositol, and allowed for an improved sugar uptake. This modification was also introduced in C. glutamicum DelAro5 yielding C. glutamicum DelAro5 PO6-iolT1 with the aim to increase intracellular PEP-availability for product formation.
Figure 3
Fig. 3

Schematic representation of the main modules of the central metabolism of C. glutamicum and introduced modifications for improving hydroxybenzoate synthesis. For an increased production of hydroxybenzoates with C. glutamicum DelAro5, different genetic modifications were introduced. This included increasing the phosphotransferase-independent sugar import with IolT1 and improving the activity of the transketolase Tkt. In parallel, reducing the GltA-mediated citrate synthase activity reduced the activity of the TCA cycle (see text for details)

In a second approach, we aimed at lowering the flux into the tricarboxylic acid (TCA) cycle as this pathway consumes pyruvate and PEP. Pyruvate is converted to the citrate synthase substrate acetyl-CoA by the pyruvate dehydrogenase complex while pyruvate and PEP are also converted to oxaloacetate by anaplerotic reactions. Citrate synthase (CS), which is encoded by the gene gltA in C. glutamicum, consumes the PEP/pyruvate-derived metabolites oxaloacetate and acetyl-CoA and catalyzes the rate-limiting step for entry of metabolites into the TCA cycle [49] (Fig. 3). It could be already shown that lowering the flux into the TCA cycle by reduced CS activity in C. glutamicum leads to an intracellular accumulation of PEP [50]. In order to investigate the effect of a reduced CS activity on hydroxybenzoate production, the native gltA promoter was replaced by a variant of the dapA promotor (termed C7) controlling expression of the dapA gene coding for the dihydrodipicolinate synthase in C. glutamicum [51]. Enzyme assays showed that combination of this C7-dapA promoter variant with the open reading frame of gltA reduced the CS activity by 90% [50]. Thus, we introduced the same modification into C. glutamicum DelAro5 yielding C. glutamicum DelAro5 C7.

At this stage, we focused on microbial 4-HB production and checked whether the modified strain backgrounds have a positive impact on product formation. Performed cultivation experiments showed that PEP-independent glucose uptake due to deregulated iolT1-expression did not increase the overall product titer but the maximum 4-HB concentration of 2.1 g/L (15.2 mM) could be reached eight hours earlier (after 22 h instead of 30 h) (Fig. 4a). The time point at which the maximum 4-HB titer in the shaking flask cultivation could be determined coincided with the depletion of glucose in the medium (data not shown). As expected, C. glutamicum DelAro5 C7 harboring pMKEx2_aroH_ubiC showed a 30% lower growth rate as a consequence of the reduced CS activity, but 4-HB production was significantly improved. During the experiments performed, this strain produced 1.9 g/L (13.8 mM) 4-HB within the first 25 h, but production continued until reaching a maximum product titer of 2.9 g/L (21.0 mM) 4-HB after 60 h of cultivation (Fig. 4a).
Figure 4
Fig. 4

Production of 4-HB with different C. glutamicum DelAro5 variants. The constructed C. glutamicum strains harboring pMKEx2_aroH_ubiC were cultivated in defined CGXII medium with 4% glucose. The heterologous gene expression was induced with 1 mM IPTG one hour after inoculation. 4-HB titers (a) and optical densities of the cultures (OD600) (b) were analyzed at time points indicated. Data represent average values and standard deviation from three biological replicates. In case no error bars are visible, the standard deviation was too small to be displayed

In the strain C. glutamicum DelAro5 C7 PO6-iolT1 pMKEx2_aroH_ubiC both effects, faster product formation and higher product titer, could be successfully combined as this strain was capable of producing 3.1 g/L (22.5 mM) 4-HB within 48 h of cultivation (Fig. 4a). With respect to growth, this new strain behaved like C. glutamicum DelAro5 C7 pMKEx2_aroH_ubiC but in principle all engineered strains reached very similar final biomass concentrations as determined by the optical density of the cultures (OD600 values ranging from 51 to 55) (Fig. 4b).

In the best-performing strain C. glutamicum DelAro5 C7 PO6-iolT1 pMKEx2_aroH_ubiC we additionally tested whether the 4-HB titer can be further increased by enhancing the supply of E4P as second shikimate pathway substrate. The transketolase, a key enzyme of the non-oxidative pentose phosphate pathway, catalyzes the formation of E4P from the glycolysis intermediates fructose-6-phosphate and glyceraldehyde-3-phosphate (Fig. 3) [52]. For additional expression of the native transketolase-encoding gene tkt, the plasmid pEKEx3_tkt was constructed. C. glutamicum DelAro5 C7 PO6-iolT1 pMKEx2_aroH_ubiC pEKEx3_tkt was characterized by a maximal growth rate of 0.19 h−1 and exhibited a slightly increased 4-HB titer of 3.3 g/L (23.9 mM), which was 10% higher compared to the strain without overexpression of tkt.

In order to find out whether this improved strain background also has an impact on PC-, 2-HB-, and 3-HB-production, the respective production plasmids were also introduced into C. glutamicum DelAro5 C7 PO6-iolT1 pEKEx3_tkt. In case of PC and 3-HB, increased product formation could be observed when the respective strains were cultivated in presence of the optimal inducer concentration determined in the initial experiments. The product titers obtained with the optimized strain were 2.0 g/L (13.0 mM) PC and 0.30 g/L (2.2 mM) 3-HB increasing the hydroxybenzoate concentration by 33 and 15%, respectively (Fig. 5). Interestingly, for 2-HB, no significant differences in the obtained product titers could be observed. All strains produced 10 ± 2 mg/L (0.07 ± 0.01 mM) 2-HB independent of the tested strain background (Fig. 5).
Figure 5
Fig. 5

Optimization of hydroxybenzoate production with C. glutamicum. The obtained hydroxybenzoate titers obtained with the C. glutamicum DelAro5 starting strain and C. glutamicum DelAro5 C7 PO6-iolT1 pEKEx3_tkt are shown. Data represent average values of three biological replicates. p-values were calculated using student’s t test with *p ≤ 0.05 and **p ≤ 0.01 (ns not significant)

Presumably, chorismate was not efficiently converted to the respective hydroxybenzoates in the 2-HB and 3-HB production strains as low concentrations of l-phenylalanine and l-tyrosine (but not l-tryptophan) in the range of 0.08–0.15 g/L (l-Phe: 0.48–0.91 mM, l-Tyr: 0.44–0.82 mM) could be detected (data not shown). Furthermore, LC–MS analysis identified 2-aminobenzoate (anthranilate) as major side product. For instance, 0.6 g/L (4.4 mM) 2-aminobenzoate was found in the best 3-HB-producing strain and 0.8 g/L (5.8 mM) 2-aminobenzoate in the best 2-HB-producing strain. 2-Aminobenzoate is the first intermediate in the l-tryptophan biosynthetic pathway and is directly deduced from chorismate due to the activity of the endogenous anthranilate synthase TrpEG [53].

Discussion

Although aromatic amino acid-producing C. glutamicum strains are available since the 1970s [54, 55], this microorganism was only recently recognized as promising host for the production of other aromatic compounds [19, 27]. Research focused on the identification of catabolic pathways for aromatic compounds in this organism, but catabolic pathways for several aromatic compounds e.g., for 3,5-dihydroxytoluene and naphthalene are still unknown [2123, 56]. Based on the known catabolic pathways for aromatic compounds, we here constructed C. glutamicum DelAro5 as a versatile platform organism for the production of aromatic compounds and demonstrated the suitability of this strain by rapidly engineering it towards PC-, 2-HB-, 3-HB- and 4-HB-synthesis. Production of PC in C. glutamicum was already reported earlier, but in this case an alternative production route was followed [44]. In this study PC was not obtained directly from 3-dehydroshikimate by its native dehydratase QsuB, but was produced via 4-HB by overexpression of the native 4-hydroxybenzoate 3-hydroxylase gene pobA. Bioreactor cultivations of the best-performing strain led to production of 1.1 g/L (7.1 mM) PC from 117 g/L (650 mM) of glucose. The same pathway including ubiC and pobA was already used earlier in an l-phenylalanine-overproducing E. coli strain, in which the competing chorismate mutase/prephenate dehydratase PheA was disrupted. This strategy led to the production of 0.27 g/L (2.0 mM) 4-HB and 0.45 g/L (2.9 mM) PC [57]. Exploitation of the 3-dehydroshikimate dehydratase AroZ in E. coli was suitable for PC production via 3-dehydroshikimate with a final product titer of 41 g/L (266 mM) [58]. This titer was achieved in an E. coli strain lacking shikimate dehydrogenase activity resulting from a mutation in the encoding gene aroE. PC is of particular interest as a precursor for the production of aliphatic polymer building blocks such as the dicarboxylic acids cis,cis-muconic acid and adipic acid [11]. Currently, there is a great interest in establishing an alternative bio-based platform for dicarboxylic acid production from renewable carbon sources. In this context, the ring-cleaving pathway starting from PC was recognized as a very promising metabolic route for dicarboxylic acid production [13, 59].

E. coli was engineered towards producing 2-HB, which also served as precursor for biosynthesis of the polymer building block cis,cis-muconic acid with this organism [60]. In a more recent study, up to 11.5 g/L (83 mM) 2-HB was produced from glucose using an E. coli strain originally engineered for l-phenylalanine production [61]. In this study, production of 2-HB was achieved by the functional introduction of two separate enzymes providing the required isochorismate synthase- and the isochorismate pyruvate lyase-activities instead of using a bifunctional salicylate synthase. In contrast, for the synthesis of 2-HB in C. glutamicum in our study, we decided for introducing of such a bifunctional salicylate synthase as this strategy requires the expression of a single heterologous gene instead of two genes. In addition, use of bifunctional enzymes eliminates the need for balancing the expression of both heterologous genes and (potentially) reduces undesired accumulation of isochorismate as pathway intermediate.

However, in the study reporting 2-HB production in E. coli mentioned above, production of other aromatic compounds including 3-HB and 4-HB was also achieved [61]. The central carbon metabolism of E. coli was engineered towards increased availability of precursor metabolites by combining different modifications in a strain already overproducing l-phenylalanine. Required strain modifications comprised replacement the PEP-dependent phosphotransferase sugar uptake system by a PEP-independent permease and simultaneous inactivation of pykF and pykA (pyruvate kinase) as well as of pheA (chorismate mutase/prephenate dehydratase) and tyrA (chorismate mutase/prephenate dehydratase), which are both involved in the conversion of chorismate to l-phenylalanine and l-tyrosine, respectively. Heterologous expression of the required genes for hydroxybenzoate synthesis in the resulting strain allowed for product titers of 2.2 g/L (15.9 mM) 3-HB and 1.8 g/L (13.0 mM) 4-HB.

In a very recent study, 4-HB production with C. glutamicum was achieved by overexpressing seven genes coding for enzymes of the shikimate pathway [62]. The obtained strain was additionally engineered by deleting genes encoding for the pyruvate kinase, the dihydroxyacetone phosphate phosphatase, the lactate dehydrogenase and the 3-dehydroshikimate dehydratase to avoid accumulation of pyruvate, dihydroxyacetone, lactate and PC as side products. Functional introduction of a highly 4-HB-resistant 4-HB synthase from Providencia rustigianii into this strain allowed for the accumulation of 36.6 g/L (265 mM) 4-HB during aerobic growth-arrested bioreactor cultivations. Any degradation of 4-HB was prevented by deletion of the 4-hydroxybenzoate 3-hydroxylase gene pobA. The obtained 4-HB titer with the constructed C. glutamicum strain is more than tenfold higher than the maximal titer of 3.3 g/L (23.9 mM) obtained in this study, but when considering the very different cultivation and production conditions, obtained product titers cannot be compared. The maximum titer of 36.6 g/L was determined during growth-arrested bioreactor cultivations of pre-grown cells in complex medium in the presence of 7.2% glucose. In contrast, the product titer of 3.3 g/L 4-HB was obtained in shaking flask cultivations with defined medium lacking any complex media ingredients and using only 4% glucose as sole carbon and energy source. However, when only comparing the strain performance of both studies during shaking flask cultivation similar titers of 20-25 mM (2.7 - 3.5 g/L) 4-HB were achieved upon expression of ubiC from E. coli.

The product 4-HB is not only an industrially relevant precursor for parabens, which find an application as preservatives in cosmetics and pharmaceuticals [63], but can be also serve as a precursor molecule for the production of plant-derived phenylpropanoids and polyphenols with C. glutamicum using a novel synthetic pathway not known to nature [64]. Combination of the heterologous 4-HB-forming pathway with the synthetic pathway for phenylpropanoid and polyphenol production would require selection of C. glutamicum DelAro5 as host strain as the catabolic pathways for 4-HB and the phenylpropanoid intermediates are abolished in this strain. This underlines that C. glutamicum DelAro5 developed in this study represents a promising strain for the production of many different natural and non-natural aromatic compounds.

For enabling a large-scale production of aromatic compounds with C. glutamicum, additional metabolic engineering work is required. This work should primarily focus on balancing the host metabolism and the heterologous pathways, e.g., for preventing side product formation. In particular during 2-HB- and 3-HB-synthesis, activity of the respective heterologous enzymes converting chorismate appeared to be rate-limiting, which presumably promoted the observed side product formation. Furthermore, identification and engineering of rate-limiting enzyme-catalyzed reaction steps either fueling or as part of the shikimate pathway will contribute to increase overall product titers.

Abbreviations

2-HB: 

2-Hydroxybenzoate (salicylate)

3-HB: 

3-Hydroxybenzoate

4-HB: 

4-Hydroxybenzoate

BTEX: 

Benzene-, toluene-, ethylbenzene- and xylene-fraction of petroleum

CS: 

Citrate synthase

E4P: 

Erythrose-4-phosphate

PC: 

3,4-Dihydroxy-benzoate (protocatechuate)

PEP: 

Phosphoenolpyruvate

TCA: 

Tricarboxylic acid cycle

Declarations

Authors’ contributions

NK and JM conceived the study; NK performed the experiments and analyzed the data. NK and JM wrote the manuscript. Both authors approved the final manuscript.

Acknowledgements

We would like to thank Christian Brüsseler for providing plasmid pK19mobsacB_PO6-iolT1.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Funding

This work was funded by the Bioeconomy Science Center (BioSC) as part of the FocusLab project “HyImPAct—Hybrid processes for important precursor and active pharmaceutical ingredients” (Grant no.: 325 – 400 002 13).

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Institute of Bio- and Geosciences, IBG-1: Biotechnology, Forschungszentrum Jülich GmbH, Jülich, Germany
(2)
Bioeconomy Science Center (BioSC), Forschungszentrum Jülich GmbH, Jülich, Germany

References

  1. Bolden AL, Kwiatkowski CF, Colborn T. New look at BTEX: are ambient levels a problem? Environ Sci Technol. 2015;49:5261–76.View ArticleGoogle Scholar
  2. Franck H-G, Stadelhofer JW. Industrial aromatic chemistry: raw materials· processes· products. New York: Springer Science & Business Media; 2012.Google Scholar
  3. Jiang M, Zhang H. Engineering the shikimate pathway for biosynthesis of molecules with pharmaceutical activities in E. coli. Curr Opin Biotechnol. 2016;42:1–6.View ArticleGoogle Scholar
  4. Herrmann KM, Weaver LM. The shikimate pathway. Annu Rev Plant Biol. 1999;50:473–503.View ArticleGoogle Scholar
  5. Grotewold E. The science of flavonoids. New York: Springer Science + Business Media; 2006.View ArticleGoogle Scholar
  6. Malik VS. Regulation of chorismate-derived antibiotic production. Adv Appl Microbiol. 1979;25:75–93.View ArticleGoogle Scholar
  7. Zhu X, Yuasa M, Okada K, Suzuki K, Nakagawa T, Kawamukai M, Matsuda H. Production of ubiquinone in Escherichia coli by expression of various genes responsible for ubiquinone biosynthesis. J Ferment Bioeng. 1995;79:493–5.View ArticleGoogle Scholar
  8. Green JM, Nichols BP. p-Aminobenzoate biosynthesis in Escherichia coli. Purification of aminodeoxychorismate lyase and cloning of pabC. J Biol Chem. 1991;266:12971–5.Google Scholar
  9. Harrison AJ, Yu M, Gårdenborg T, Middleditch M, Ramsay RJ, Baker EN, Lott JS. The structure of MbtI from Mycobacterium tuberculosis, the first enzyme in the biosynthesis of the siderophore mycobactin, reveals it to be a salicylate synthase. J Bacteriol. 2006;188:6081–91.View ArticleGoogle Scholar
  10. Lee J-H, Wendisch VF. Biotechnological production of aromatic compounds of the extended shikimate pathway from renewable biomass. J Biotechnol. 2017;257:211–21.View ArticleGoogle Scholar
  11. Weber C, Brückner C, Weinreb S, Lehr C, Essl C, Boles E. Biosynthesis of cis, cis-muconic acid and its aromatic precursors, catechol and protocatechuic acid, from renewable feedstocks by Saccharomyces cerevisiae. Appl Environ Microbiol. 2012;78:8421–30.View ArticleGoogle Scholar
  12. Hansen EH, Møller BL, Kock GR, Bünner CM, Kristensen C, Jensen OR, Okkels FT, Olsen CE, Motawia MS, Hansen J. De novo biosynthesis of vanillin in fission yeast (Schizosaccharomyces pombe) and baker’s yeast (Saccharomyces cerevisiae). Appl Environ Microbiol. 2009;75:2765–74.View ArticleGoogle Scholar
  13. Polen T, Spelberg M, Bott M. Toward biotechnological production of adipic acid and precursors from biorenewables. J Biotechnol. 2013;167:75–84.View ArticleGoogle Scholar
  14. Becker J, Zelder O, Häfner S, Schröder H, Wittmann C. From zero to hero—design-based systems metabolic engineering of Corynebacterium glutamicum for l-lysine production. Metab Eng. 2011;13:159–68.View ArticleGoogle Scholar
  15. Koffas MA, Jung GY, Stephanopoulos G. Engineering metabolism and product formation in Corynebacterium glutamicum by coordinated gene overexpression. Metab Eng. 2003;5:32–41.View ArticleGoogle Scholar
  16. Ikeda M, Katsumata R. Metabolic engineering to produce tyrosine or phenylalanine in a tryptophan-producing Corynebacterium glutamicum strain. Appl Environ Microbiol. 1992;58:781–5.Google Scholar
  17. Hagino H, Nakayama K. L-Tryptophan production by analog-resistant mutants derived from a phenylalanine and tyrosine double auxotroph of Corynebacterium glutamicum. Agric Biol Chem. 1975;39:343–9.Google Scholar
  18. Ikeda M. Amino acid production processes. In: Faurie R, Thommel J, editors. Microbial production of l-amino acids. New York: Springer Science & Business Media; 2003. p. 1–35.Google Scholar
  19. Kogure T, Kubota T, Suda M, Hiraga K, Inui M. Metabolic engineering of Corynebacterium glutamicum for shikimate overproduction by growth-arrested cell reaction. Metab Eng. 2016;38:204–16.View ArticleGoogle Scholar
  20. Kubota T, Watanabe A, Suda M, Kogure T, Hiraga K, Inui M. Production of para-aminobenzoate by genetically engineered Corynebacterium glutamicum and non-biological formation of an N-glucosyl byproduct. Metab Eng. 2016;38:322–30.View ArticleGoogle Scholar
  21. Shen X-H, Zhou N-Y, Liu S-J. Degradation and assimilation of aromatic compounds by Corynebacterium glutamicum: another potential for applications for this bacterium? Appl Microbiol Biotechnol. 2012;95:77–89.View ArticleGoogle Scholar
  22. Kallscheuer N, Vogt M, Kappelmann J, Krumbach K, Noack S, Bott M, Marienhagen J. Identification of the phd gene cluster responsible for phenylpropanoid utilization in Corynebacterium glutamicum. Appl Microbiol Biotechnol. 2016;100:1871–81.View ArticleGoogle Scholar
  23. Du L, Ma L, Qi F, Zheng X, Jiang C, Li A, Wan X, Liu S-J, Li S. Characterization of a unique pathway for 4-cresol catabolism initiated by phosphorylation in Corynebacterium glutamicum. J Biol Chem. 2016;291:6583–94.View ArticleGoogle Scholar
  24. Merkens H, Beckers G, Wirtz A, Burkovski A. Vanillate metabolism in Corynebacterium glutamicum. Curr Microbiol. 2005;51:59–65.View ArticleGoogle Scholar
  25. Shen X, Liu S. Key enzymes of the protocatechuate branch of the β-ketoadipate pathway for aromatic degradation in Corynebacterium glutamicum. Sci China Ser C. 2005;48:241–9.Google Scholar
  26. Liu Y-B, Long M-X, Yin Y-J, Si M-R, Zhang L, Lu Z-Q, Wang Y, Shen X-H. Physiological roles of mycothiol in detoxification and tolerance to multiple poisonous chemicals in Corynebacterium glutamicum. Arch Microbiol. 2013;195:419–29.View ArticleGoogle Scholar
  27. Kallscheuer N, Vogt M, Stenzel A, Gätgens J, Bott M, Marienhagen J. Construction of a Corynebacterium glutamicum platform strain for the production of stilbenes and (2S)-flavanones. Metab Eng. 2016;38:47–55.View ArticleGoogle Scholar
  28. Keilhauer C, Eggeling L, Sahm H. Isoleucine synthesis in Corynebacterium glutamicum: molecular analysis of the ilvB-ilvN-ilvC operon. J Bacteriol. 1993;175:5595–603.View ArticleGoogle Scholar
  29. Bertani G. Studies on Lysogenesis I: the mode of phage liberation by lysogenic Escherichia coli1. J Bacteriol. 1951;62:293.Google Scholar
  30. Sambrook J, Russell D. Molecular cloning, vol. 1–3. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2001.Google Scholar
  31. Eggeling L, Bott M. Handbook of Corynebacterium glutamicum. Boca Raton: CRC Press; 2005.View ArticleGoogle Scholar
  32. Whitman L, Gore M, Ness J, Theodorou E, Gustafsson C, Minshull J. Rapid, scarless cloning of gene fragments using the electra vector system. Genet Eng Biotechnol. 2013;33:42.Google Scholar
  33. Schäfer A, Tauch A, Jäger W, Kalinowski J, Thierbach G, Pühler A. Small mobilizable multi-purpose cloning vectors derived from the Escherichia coli plasmids pK18 and pK19: selection of defined deletions in the chromosome of Corynebacterium glutamicum. Gene. 1994;145:69–73.View ArticleGoogle Scholar
  34. Niebisch A, Bott M. Molecular analysis of the cytochrome bc1-aa3 branch of the Corynebacterium glutamicum respiratory chain containing an unusual diheme cytochrome c1. Arch Microbiol. 2001;175:282–94.View ArticleGoogle Scholar
  35. Teramoto H, Inui M, Yukawa H. Regulation of expression of genes involved in quinate and shikimate utilization in Corynebacterium glutamicum. Appl Environ Microbiol. 2009;75:3461–8.View ArticleGoogle Scholar
  36. Pelludat C, Brem D, Heesemann J. Irp9, encoded by the high-pathogenicity island of Yersinia enterocolitica, is able to convert chorismate into salicylate, the precursor of the siderophore yersiniabactin. J Bacteriol. 2003;185:5648–53.View ArticleGoogle Scholar
  37. Andexer JN, Kendrew SG, Nur-e-Alam M, Lazos O, Foster TA, Zimmermann A-S, Warneck TD, Suthar D, Coates NJ, Koehn FE. Biosynthesis of the immunosuppressants FK506, FK520, and rapamycin involves a previously undescribed family of enzymes acting on chorismate. Proc Natl Acad Sci USA. 2011;108:4776–81.View ArticleGoogle Scholar
  38. Siebert M, Severin K, Heide L. Formation of 4-hydroxybenzoate in Escherichia coli: characterization of the ubiC gene and its encoded enzyme chorismate pyruvate-lyase. Microbiology. 1994;140:897–904.View ArticleGoogle Scholar
  39. Shen X-H, Jiang C-Y, Huang Y, Liu Z-P, Liu S-J. Functional identification of novel genes involved in the glutathione-independent gentisate pathway in Corynebacterium glutamicum. Appl Environ Microbiol. 2005;71:3442–52.View ArticleGoogle Scholar
  40. Li P-P, Li D-F, Liu D, Liu Y-M, Liu C, Liu S-J. Interaction between DAHP synthase and chorismate mutase endows new regulation on DAHP synthase activity in Corynebacterium glutamicum. Appl Microbiol Biotechnol. 2013;97:10373–80.View ArticleGoogle Scholar
  41. Zurawski G, Gunsalus R, Brown K, Yanofsky C. Structure and regulation of aroH, the structural gene for the tryptophan-repressible 3-deoxy-d-arabino-heptulosonic acid-7-phosphate synthetase of Escherichia coli. J Mol Biol. 1981;145:47–73.View ArticleGoogle Scholar
  42. Brune I, Jochmann N, Brinkrolf K, Hüser AT, Gerstmeir R, Eikmanns BJ, Kalinowski J, Pühler A, Tauch A. The IclR-type transcriptional repressor LtbR regulates the expression of leucine and tryptophan biosynthesis genes in the amino acid producer Corynebacterium glutamicum. J Bacteriol. 2007;189:2720–33.View ArticleGoogle Scholar
  43. Zhang C, Kang Z, Zhang J, Du G, Chen J, Yu X. Construction and application of novel feedback-resistant 3-deoxy-D-arabino-heptulosonate-7-phosphate synthases by engineering the N-terminal domain for l-phenylalanine synthesis. FEMS Microbiol Lett. 2014;353:11–8.View ArticleGoogle Scholar
  44. Okai N, Miyoshi T, Takeshima Y, Kuwahara H, Ogino C, Kondo A. Production of protocatechuic acid by Corynebacterium glutamicum expressing chorismate-pyruvate lyase from Escherichia coli. Appl Microbiol Biotechnol. 2016;100:135–45.View ArticleGoogle Scholar
  45. Malin G, Bourd G. Phosphotransferase-dependent glucose transport in Corynebacterium glutamicum. J Appl Microbiol. 1991;71:517–23.Google Scholar
  46. Lindner SN, Seibold GM, Krämer R, Wendisch VF. Impact of a new glucose utilization pathway in amino acid-producing Corynebacterium glutamicum. Bioeng Bugs. 2011;2:291–5.View ArticleGoogle Scholar
  47. Klaffl S, Brocker M, Kalinowski J, Eikmanns BJ, Bott M. Complex regulation of the phosphoenolpyruvate carboxykinase gene pck and characterization of its GntR-type regulator IolR as a repressor of myo-inositol utilization genes in Corynebacterium glutamicum. J Bacteriol. 2013;195:4283–96.View ArticleGoogle Scholar
  48. Brüsseler C, Radek A, Tenhaef N, Krumbach K, Noack S, Marienhagen J. The myo-inositol/proton symporter IolT1 contributes to D-xylose uptake in Corynebacterium glutamicum. Bioresour Technol. 2018;249:953–61.View ArticleGoogle Scholar
  49. Eikmanns BJ, Thum-Schmitz N, Eggeling L, Lüdtke K-U, Sahm H. Nucleotide sequence, expression and transcriptional analysis of the Corynebacterium glutamicum gltA gene encoding citrate synthase. Microbiology. 1994;140:1817–28.View ArticleGoogle Scholar
  50. van Ooyen J, Noack S, Bott M, Reth A, Eggeling L. Improved l-lysine production with Corynebacterium glutamicum and systemic insight into citrate synthase flux and activity. Biotechnol Bioeng. 2012;109:2070–81.View ArticleGoogle Scholar
  51. Vašicová P, Pátek M, Nešvera J, Sahm H, Eikmanns B. Analysis of the Corynebacterium glutamicum dapA promoter. J Bacteriol. 1999;181:6188–91.Google Scholar
  52. Ikeda M, Okamoto K, Katsumata R. Cloning of the transketolase gene and the effect of its dosage on aromatic amino acid production in Corynebacterium glutamicum. Appl Microbiol Biotechnol. 1999;51:201–6.View ArticleGoogle Scholar
  53. Hagino H, Nakayama K. Regulatory properties of anthranilate synthetase from Corynebacterium glutamicum. Agric Biol Chem. 1975;39:323–30.Google Scholar
  54. Hagino H, Nakayama K. L-Tyrosine production by analog-resistant mutants derived from a phenylalanine auxotroph of Corynebacterium glutamicum. Agric Biol Chem. 1973;37:2013–23.View ArticleGoogle Scholar
  55. Hagino H, Nakayama K. L-Phenylalanine production by analog-resistant mutants of Corynebacterium glutamicum. Agric Biol Chem. 1974;38:157–61.View ArticleGoogle Scholar
  56. Shen X-H, Li T, Xu Y, Zhou N-Y, Liu S-J. Transport, degradation and assimilation of aromatic compounds and their regulation in Corynebacterium glutamicum. In: Burkovski A, editor. Corynebacterium glutamicum—from systems biology to biotechnological applications. Poole: Caister Academic Press; 2015. p. 83–110.View ArticleGoogle Scholar
  57. Pugh S, McKenna R, Osman M, Thompson B, Nielsen DR. Rational engineering of a novel pathway for producing the aromatic compounds p-hydroxybenzoate, protocatechuate, and catechol in Escherichia coli. Process Biochem. 2014;49(11):1843–50.View ArticleGoogle Scholar
  58. Li W, Xie D, Frost JW. Benzene-free synthesis of catechol: interfacing microbial and chemical catalysis. J Am Chem Soc. 2005;127(9):2874–82.View ArticleGoogle Scholar
  59. Vardon DR, Franden MA, Johnson CW, Karp EM, Guarnieri MT, Linger JG, Salm MJ, Strathmann TJ, Beckham GT. Adipic acid production from lignin. Energy Environ Sci. 2015;8:617–28.View ArticleGoogle Scholar
  60. Lin Y, Sun X, Yuan Q, Yan Y. Extending shikimate pathway for the production of muconic acid and its precursor salicylic acid in Escherichia coli. Metab Eng. 2014;23:62–9.View ArticleGoogle Scholar
  61. Noda S, Shirai T, Oyama S, Kondo A. Metabolic design of a platform Escherichia coli strain producing various chorismate derivatives. Metab Eng. 2016;33:119–29.View ArticleGoogle Scholar
  62. Kitade Y, Hashimoto R, Suda M, Hiraga K, Inui M. Production of 4-hydroxybenzoic acid by an aerobic growth-arrested bioprocess using metabolically engineered Corynebacterium glutamicum. Appl Environ Microbiol. 2018. https://doi.org/10.1128/AEM.02587-17.Google Scholar
  63. Cabaleiro N, De La Calle I, Bendicho C, Lavilla I. An overview of sample preparation for the determination of parabens in cosmetics. Trends Anal Chem. 2014;57:34–46.View ArticleGoogle Scholar
  64. Kallscheuer N, Vogt M, Marienhagen J. A novel synthetic pathway enables microbial production of polyphenols independent from the endogenous aromatic amino acid metabolism. ACS Synth Biol. 2016;6:410–5.View ArticleGoogle Scholar
  65. Kortmann M, Kuhl V, Klaffl S, Bott M. A chromosomally encoded T7 RNA polymerase-dependent gene expression system for Corynebacterium glutamicum: construction and comparative evaluation at the single-cell level. Microb Biotechnol. 2015;8:253–65.View ArticleGoogle Scholar
  66. Gande R, Dover LG, Krumbach K, Besra GS, Sahm H, Oikawa T, Eggeling L. The two carboxylases of Corynebacterium glutamicum essential for fatty acid and mycolic acid synthesis. J Bacteriol. 2007;189:5257–64.View ArticleGoogle Scholar

Copyright

© The Author(s) 2018

Advertisement